Available Clinical Trials for Pet Cancer Research

Updates: Available Clinical Trials for Pet Cancer Research

Part of the TVCR’s goal is to empower pet-owners with information. We know that pet-owners will go to great lengths to care for the health and well-being of their pet, but sometimes, they just don’t know where to start.

That’s why the TVCR has added a new feature to our site: a clinical trials listing.

As we grow and develop we will build out this searchable section to make it easier for pet-owners to access information about new and existing trials.

For more information on clinical trials, please see our listing.

 

CALIFORNIA

UC-Davis

Lymphography of Lung Tumors

Study Details:

Species: Canines

Tumor: Lung tumors

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The objective of this study is to better understand the metastatic spread of primary lung tumors to the local lymph nodes to improve surgical approaches to these lymph nodes.  Understanding the lymph node status is very important in the prognosis and treatment of this disease.

Lymphography of Anal Sac Adenocarcinoma

Study Details:

Species: Canines

Tumor: Anal sac tumors

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The objective of this study is to better understand the metastatic spread of anal sac gland tumors to the local lymph nodes.
All dogs must be examined by a VMTH oncology, radiation oncology service or soft tissue surgery veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:

• Confirmed diagnosis via aspiration cytology
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis all within two weeks of enrollment (referring blood work is acceptable as long as it was performed at a commercial lab)

 

Chemoembolization of Nasal Tumors

Study Details:

Species: Canines

Tumor: patients with nasal tumors

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The objective of this study is evaluate alternative treatment options for patients with nasal tumors.  Radiation therapy is still considered the gold standard of treatment for this disease, however clients who do not wish to pursue radiation therapy, or whose dog has failed radiation therapy may be eligible for participation in this study.

All dogs must be examined by a VMTH oncology, internal medicine, radiation oncology service or soft tissue surgery veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial. Inclusion Criteria:

• Confirmed diagnosis via cytology or histopathology
• CT scan performed by the UCDAVIS Radiology Department within 3 weeks of enrollment.  If you are coming to UCDavis for workup of your dog’s nasal mass, nasal discharge, or nasal bleeding, PLEASE contact Dr. Steffey or discuss your interest in this study with your attending clinician BEFORE your CT scan is scheduled.
• CBC, Chemistry Panel and Urinalysis all within two weeks of enrollment (referring blood work is acceptable as long as it was performed at a commercial lab)
• Clients *must* be willing to return at 1 month and 4 months for study rechecks, including a CT scan under brief general anesthesia.  There is no charge for these rechecks, but it is imperative that the patient return for re-evaluation.

Cryoablation of Nasal Tumors

Study Details:

Species: Canines

Tumor: patients with nasal tumors

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The objective of this study is evaluate alternative treatment options for patients with nasal tumors.  Radiation therapy is still considered the gold standard of treatment for this disease, however clients who do not wish to pursue radiation therapy may be eligible for participation in this study. Inclusion Criteria:

• Confirmed diagnosis via cytology or histopathology
• CT scan demonstrating extent of nasal mass to determine if this treatment may be safely administered
• CBC, Chemistry Panel and Urinalysis all within two weeks of enrollment (referring blood work is acceptable as long as it was performed at a commercial lab)
• Clients *must* be willing to return for study rechecks, including a CT scan under brief general anesthesia.  There is no charge for these rechecks, but it is imperative that the patient return for re-evaluation.

VEGFR Ultrasound Study

Study Details:

Species: Canines

Tumor: Soft Tissue Sarcoma, Transitional Cell Carcinoma of the bladder or Thyroid Cancer

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The purpose of this study is to assess a novel ultrasound technique for its ability to approximate a tumors angiogenic potential.  This technique involves the intravenous injection of a contrast agent that is targeted to a specific feature (vascular endothelial growth factor receptor or VEGFR density) of highly angiogenic blood vessels in the tumor. Our goal is to use this ultrasound technique to measure VEGFR density before therapy is instituted and compare this to special VEGFR stains of biopsied tumor tissue to ensure that the ultrasound technique truly approximates angiogenesis. This may allow us to prognosticate regarding future behavior of the tumor.  In addition, we believe that this measure may act as a predictor of response to chemotherapy.

 

Pathologic fracture risk of tumor-bearing canine forelimbs

Study Details:

Species: Canines

Tumor: Osteosarcoma

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The objective of this study is to measure the reduction in bone strength due to the presence of cancer in the radius/ulna of the dog by measuring the force at which these bones break in a mechanical testing device AFTER removal from the patient.   Tumor–bearing bones will be obtained from clinical canine patients that are undergoing amputation of the affected limb as standard of care treatment for their bone tumor, and testing of these limbs will not affect care received by these patients.  Computed tomography (CT) images of these bones will also be obtained, and this study will seek to correlate calculated CT indices of bone strength with the biomechanically measured bone strength.  It is hoped that correlations found will allow prediction of patients at most risk for pathologic fracture, improve patient selection for current treatment options such as palliative radiation therapy, and aid in the development of alternative limb-salvage procedures.

 

Preclinical evaluation of a novel synthetic antibody for treatment of spontaneously occurring B-cell lymphoma in dogs.

Study Details:

Species: Canines

Tumor: Dogs with Lymphoma/SH-7139

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study It is possible that treatment with SH 7139 will be an effective therapy for your dog’s lymphoma, and may result in remission.  It is hoped that with the information obtained from this trial, SH 7139 can proceed to clinical trials in people with non-Hodgkin’s lymphoma. The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous treatment, and relapsed patients that may have failed other treatment options.

 

Novel Product Targeting T-Cell and B-Cell Lymphomas in Combination with Doxorubicin

Study Details:

Species: Canines

Tumor: Dogs with T-Cell and B-Cell Lymphomas

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages. Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is urgently needed.

New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for humans.

This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting lymphoma cells in laboratory studies. This study proposes the use of this Product to obtain additional data about its safety and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.

 

P.A.G.

Study Details:

Species: Canines

Tumor: Dogs with T-Cell and B-Cell Lymphomas

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study The goal of this study is to evaluate the efficacy of using the enzyme Pegylated Arginine Deiminase (non-chemotherapy drug) as a subcutaneous injection. Eligibility Requirements:
Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:

• Confirmed diagnosis
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)

Adriamycin vs. Epirubicin

Study Details:

Species: Canines

Tumor: Dogs with Hemangiosarcomas

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study Comparing Adriamycin vs. Epirubicin over the course of six doses. Inclusion criteria:  Canine patients that have Splenic Hemangiosarcoma and has ruptured with a biopsy to confirm NO liver metastasis.

 

Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam

Study Details:

Species: Canines

Tumor: Dogs with Anal sac Adenocarcinoma/gross disease

For more information: Visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm” or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study Comparing the two different agents, Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam in patients with anal sac adenocarcinomas or gross disease.

 

Evaluation of a novel anticancer agent in tumor bearing dogs to define its pharmacokinetic profile and biological activity:COTCO18

Study Details:

Species: Canines

Tumor: Mammary Carcinoma, Melanoma, Squamous Cell Carcinoma, or Soft Tissue Sarcoma

For more information: please visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm”

Purpose of Study: This clinical trial is led by the National Cancer Institute (NCI) and conducted through the Comparative Oncology Trials Consortium.
A clinical trial of a novel anticancer agent in tumor bearing dogs with either melanoma, soft tissue sarcoma, squamous cell carcinoma or mammary carcinoma intended to define biological changes in tumor and surrogate tissues following drug exposure that may elucidate mechanisms of action and potential biomarkers of its activity. The study period is 21 days.
Costs associated with this study will be provided during the dog’s participation. In the event there are any complications arising during the study period the dog’s management will be covered by study funds. This would include any unanticipated hospitalizations at the patient’s Veterinary Teaching Hospital.

ALABAMA

Auburn University

Canine Nasal Carcinoma

Study Details: Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of canine nasal carcinoma.

Species: Canines

Tumor: Nasal Carcinoma

Purpose of study: All tumors must develop new blood vessels in order to grow. Palladia is a tyrosine kinase inhibitor that inhibits the development of new blood vessels by targeting receptors called vascular endothelial growth factor receptors. These receptors have been documented to occur in canine nasal tumors and early reports indicate that Palladia has primary activity in these tumors. Palladia has also been shown to sensitize tumor tissues to the effects of radiation therapy. Because of these findings, clinical investigation of Palladia as therapy for nasal carcinomas, alone or in combination with radiation therapy is needed to know if we can increase our efficacy in controlling these tumors in comparison to radiation therapy alone. We also need to monitor for any side effects.

• For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690

Soft Tissue Sarcomas, Oral Melanomas, Head and Neck Carcinomas and Mammary Carcinomas

Study Details: COTC trial, this trial is to investigate the use of iniparib, a drug used to treat various cancers in humans and in dogs.

Species: Canines

Tumor: soft tissue sarcoma, oral melanoma, carcinoma of head, neck and mammary.

Purpose of study: COTC trial in soft tissue sarcomas, oral melanomas, head and neck carcinomas, and mammary carcinomas: Multiple visits to the hospital are required for drug administration and serial blood and tumor samples over the course of 15-22 days. At the end of the study, $1000 is credited to your pet’s account in order to further treat the tumor.

• For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690

 

Feline Oral Squamous Cell Carcinoma

Study Details: Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of feline oral squamous cell carcinoma.

Species: Canines

Tumor: feline oral squamous cell carcinoma

Purpose of study: Palladia is a tyrosine kinase inhibitor that affects the development of blood vessels by targeting receptor tyrosine kinases within tumors. By blocking the signaling of these pathways tumor growth can be slowed. The presence of these receptors (VEGF and VEGFRs) has been well documented in human oral squamous cell carcinomas.  This has not been evaluated yet in feline tumors.  Evidence continues to accumulate indicating that Palladia can also increase the sensitivity of tumor cells to radiation therapy and that Palladia has some primary activity in feline oral squamous cell carcinomas. Because of these effects, clinical investigation of Palladia as therapy for feline oral squamous cell carcinoma alone or in combination with radiation therapy is indicated.

• For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690, or smith30@auburn.edu

COTC Lymphoma Trial

Study Details: indenoisoquinolines, new chemotherapy drugs for potential use in people and dogs.

Species: Canines

Tumor: lymphoma

Purpose of study: COTC trial in lymphoma: This trial is to investigate the use of indenoisoquinolines, new chemotherapy drugs for potential use in people and dogs. Multiple visits to the hospital are required for drug administration and serial blood and tumor samples over the course of 28 days. At the end of the study, $1000 is credited to your pet’s account in order to further treat the tumor.

• For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690, or smith30@auburn.edu

 

Soft tissue sarcoma Trial with chlorambucil

Study Details: This trial is to investigate the effect of chlorambucil, an oral chemotherapy drug.

Species: Canines

Tumor: soft tissue sarcoma

Purpose of study: This trial is to investigate the effect of chlorambucil, an oral chemotherapy drug, on the immune system of dogs with soft tissue sarcomas. The tumors can be present or incompletely removed by surgery. The study requires blood and lymph node tissue samples to be taken over 3 visits to our hospital over one month. The study covers the cost of the drug and the visits. The owner is responsible for further recommended treatment.

• For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690, or smith30@auburn.edu OR visit “http://www.vetmed.auburn.edu/trials#.UeYeRW05OSo”

 

 

University of Pennsylvania: Mason Bone Cancer Study

University of Pennsylvania: Mason Bone Cancer Study

Study details:

Species: Canine

Tumor: Osteosarcoma

For more information visit: http://www.vet.upenn.edu/FacultyandDepartments/Pathobiology/ClinicalTrialsinPathobiology/CancerVaccineforDogswithOsteosarcoma/tabid/2345/Default.aspx or e-mail Dr. Nicola Mason at nmason@vet.upenn.edu

Purpose of study: The purpose of this study is to determine whether a recombinant L. moncytogenes vaccine can elicit anti-tumor immunity and prolong survival in dogs with cancer of their long bones (appendicular osteosarcoma (OSA)). More details of the trial can be found in the link above.